查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930043

馬匹健康市場規模、佔有率、成長及全球產業分析：按類型、應用和地區劃分的洞察與預測（2025-2034）

Equine Health Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 164 Pages | 商品交期: 請詢問到貨日

價格

馬匹健康市場成長驅動因素

全球馬匹健康市場專注於透過使用藥物、疫苗和飼料添加劑來預防、診斷和治療影響馬匹的疾病。馬匹容易受到多種傳染性和非傳染性疾病的侵襲，其中一些是地方性流行病，有些則是由環境變化和人畜共患病風險引起的。疾病流行率上升、人們對馬匹福利的意識不斷增強以及政府和機構支持力度加大，正推動全球馬匹健康市場穩步增長。

市場規模及預測

根據 Fortune Business Insights 數據顯示，2025 年全球馬匹健康市場規模為 22.1 億美元。預計到 2026 年將成長至 23.6 億美元，並在 2034 年進一步擴大至 40.8 億美元，在預測期（2026-2034 年）內複合年增長率 (CAGR) 為 7.07%。

北美地區在全球市場中佔領先地位，預計到 2025 年將佔 37.43% 的市場佔有率，這主要得益於其龐大的馬匹數量、先進的獸醫基礎設施以及馬匹保健產品的高普及率。

市場驅動因素

市場成長的主要驅動因素是馬匹疾病的增加，包括西尼羅河病毒、馬流感、狂犬病、皰疹病毒、破傷風和波托馬克馬熱。根據美國農業部統計，2019年美國確診了90例西尼羅河病毒感染病例和184例東部馬腦炎病例。這些疾病爆發的增加顯著提高了對預防性疫苗和治療的需求。

此外，人們對人畜共患病傳播的認識不斷提高，獸醫組織和政府的措施也促進了常規疫苗接種和預防保健。加大研發投入以提高疫苗安全性和藥物有效性也有助於市場擴張。

新冠疫情的影響

新冠疫情對馬匹健康市場的影響程度為中等。 2020年，由於供應鏈中斷、旅行限制以及獸醫到訪馬場次數減少，市場成長放緩。然而，隨著疫情後期獸醫院和診所的重新開放，市場出現了小幅正成長。

例如，碩騰服務有限公司（Zoetis Services LLC）2020年在馬匹領域的淨銷售額為2.15億美元，2021年較上年增長22.3%。隨著獸醫診所恢復正常運營，預計市場將在2021年和2022年恢復到疫情前的成長軌道，從而穩定收入並支持長期成長。

市場趨勢

馬匹健康市場最顯著的趨勢之一是向鼻內給藥的轉變。鼻內疫苗可以減輕肌肉酸痛並增強局部免疫力，尤其是在預防呼吸道疾病方面。

例如，2020 年 9 月，勃林格殷格翰推出了 Aservo EquiHaler，這是首個獲得美國食品藥物管理局 (FDA) 批准用於治療嚴重馬哮喘的吸入式疫苗。領先企業持續的技術創新和開創性產品的推出正在推動市場成長。

成長驅動因素

馬匹疾病發生率的快速成長仍然是關鍵的成長驅動因素。英國的馬流感等地方性疾病以及全球病毒性疾病的爆發日益增多，正在推動對疫苗和藥物的需求。此外，諸如英國馬術聯合會發起的 "降低疾病風險聯合倡議" （2022 年）等提高公眾意識的活動，正在推廣預防性醫療保健措施，進一步支持市場成長。

限制因子

儘管成長前景強勁，但合格的馬獸醫短缺仍然是一個挑戰，尤其是在新興地區和農村地區。根據澳洲廣播公司新聞（ABC News，2023）報道，澳洲只有2-3%的獸醫畢業生會專攻馬科醫學，限制了馬匹獲得醫療服務的機會。

此外，由於操作不當、免疫反應差異和病原體變異等因素導致的疫苗失效案例，引起了馬主的擔憂，並可能限制產品的使用。

細分市場分析

  • 依藥物類別劃分：2026年，製藥類藥物佔市場主導地位，市佔率達54.78%。這主要得益於強大的研發實力和新產品上市，例如維克（Virbac）的類固醇片劑 "Equipred" 。
  • 依疾病分類：其他疾病類別佔市場主導地位，涵蓋諸如腹痛、跛行和萊姆病等疾病。馬流感類別在2026年佔了21.36%的市場。
  • 依分銷管道分類：獸醫醫院和診所佔最大佔有率，這主要得益於全球專業馬科診所數量的成長。

區域洞察

2026年，北美市場規模將達到8.8億美元，主要得益於美國約720萬匹馬的龐大數量。歐洲由於馬流感等疾病的爆發，繼續佔有重要佔有率。亞太地區預計將以最高的複合年增長率增長，這主要得益於中國、日本和印度的強勁增長，以及公眾意識的提高和政府舉措的支持。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 統計：主要國家/地區馬匹數量（2025 年）
  • 主要國家/地區馬匹健康監管環境（2025 年）
  • 主要產業趨勢（併購、合作、新產品發表等）
  • 馬匹健康管理技術進步
  • 新冠疫情的影響市場

第五章 全球馬匹健康市場分析、洞察與預測（2021-2034）

  • 市場分析、洞察與預測 - 按產品分類
    • 依藥物類型分類
      • 抗感染藥
      • 抗發炎藥
      • 驅蟲藥
      • 其他
    • 疫苗類型分類
      • 滅活​​疫苗
      • 減毒活疫苗
      • 重組疫苗
      • 其他
    • 飼料添加劑
  • 市場分析、洞察與預測 - 按疾病類型分類
    • 西尼羅河病毒
    • 馬狂犬病
    • 馬流感
    • 馬皰疹病毒
    • 波托馬克河馬熱
    • 破傷風
    • 其他
  • 市場分析、洞察與預測 - 按銷售管道劃分
    • 獸醫院和診所
    • 零售藥局和藥房
    • 其他
  • 市場分析、洞察與預測 - 按地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美馬匹健康市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲馬匹健康市場分析、洞察與預測預測，2021-2034

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章：亞太地區馬匹健康市場分析、洞察與預測，2021-2034

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲馬匹健康市場分析、洞察與預測，2021-2034

  • 依國家/地區
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家/地區

第十章：中東和非洲馬匹健康市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會 (GCC)
    • 南非
    • 其他中東和非洲國家/地區

第十一章：競爭分析

  • 全球市佔率分析（2025）
  • 公司簡介
    • 碩騰服務有限公司 (Zoetis Services LLC)
    • 雪華 (Ceva)
    • 禮來 (Elanco)
    • 勃林格殷格翰國際有限公司 (Boehringer Ingelheim International GmbH)
    • 維托奎諾 (Vetoquinol)
    • 新健公司 (Neogen Corporation)
    • 維克 (Virbac)
    • 默克公司 (Merck & Co.)公司
    • 諾布魯克
    • 普瑞納動物營養股份有限公司
    • 京日製藥株式會社
    • 英國馬匹產品股份有限公司
Product Code: FBI101416

Growth Factors of equine health Market

The global equine health market focuses on the prevention, diagnosis, and treatment of diseases affecting horses through the use of drugs, vaccines, and supplemental feed additives. Horses are vulnerable to a wide range of infectious and non-infectious diseases, some of which are endemic, while others emerge due to environmental changes and zoonotic risks. Rising disease prevalence, growing awareness of equine welfare, and increasing government and institutional support are driving steady growth in the global equine health market.

Market Size and Forecast

According to Fortune Business Insights, the global equine health market was valued at USD 2.21 billion in 2025. The market is projected to grow to USD 2.36 billion in 2026 and further expand to USD 4.08 billion by 2034, registering a CAGR of 7.07% during the forecast period (2026-2034).

North America dominated the global market with a share of 37.43% in 2025, supported by a strong equine population, advanced veterinary infrastructure, and high adoption of equine healthcare products.

Market Drivers

A major driver of market growth is the increasing prevalence of equine diseases, including West Nile virus, equine influenza, rabies, herpes virus, tetanus, and Potomac horse fever. According to the U.S. Department of Agriculture, there were 90 cases of West Nile virus and 184 cases of eastern equine encephalitis in the U.S. in 2019. Such disease incidence has significantly increased the demand for preventive vaccines and therapeutic drugs.

Additionally, growing awareness of zoonotic disease transmission and initiatives by veterinary organizations and governments are encouraging regular vaccination and preventive care. Rising investments in research and development (R&D) to improve vaccine safety and drug efficacy are also contributing to market expansion.

COVID-19 Impact

The COVID-19 pandemic had a moderate impact on the equine health market. In 2020, growth slowed due to supply chain disruptions, travel restrictions, and reduced veterinary visits to equine farms. However, the market witnessed slight positive growth as veterinary hospitals and clinics resumed operations in the second half of the pandemic.

For instance, Zoetis Services LLC generated USD 215.0 million in net sales from its horse segment in 2020, followed by a 22.3% year-on-year increase in 2021. As veterinary visits normalized, the market returned to its pre-COVID growth trajectory by 2021-2022, stabilizing revenues and supporting long-term growth.

Market Trends

One of the most prominent trends in the equine health market is the shift toward intranasal routes of administration. Intranasal vaccines reduce muscle soreness and enhance local immunity, particularly for respiratory diseases.

For example, in September 2020, Boehringer Ingelheim launched Aservo EquiHaler, the first FDA-approved inhalant therapy for horses with severe equine asthma. Continuous innovation and advanced product launches by key players are accelerating market growth.

Growth Factors

The surge in equine disease prevalence remains a key growth factor. Endemic diseases such as equine influenza in the U.K. and increasing viral outbreaks globally are driving demand for vaccines and drugs. Moreover, rising awareness initiatives, such as the British Equestrian's "Reducing Disease Risk Together" campaign (2022), are improving adoption of preventive healthcare practices, further boosting market growth.

Restraining Factors

Despite strong growth prospects, the market faces challenges due to the shortage of qualified equine veterinarians, especially in emerging and rural regions. According to ABC News (2023), only 2-3% of new veterinary graduates in Australia pursue equine medicine, limiting access to equine care services.

Additionally, vaccine failure events, caused by factors such as improper handling, immune response variability, or pathogen mutation, have raised concerns among horse owners, potentially restricting product adoption.

Segmentation Analysis

  • By Product: The drug class segment dominated the market with a 54.78% share in 2026, driven by strong R&D and product launches such as Virbac's Equipred steroid tablets.
  • By Disease Type: The others segment led the market, covering diseases such as colic, lameness, and Lyme disease. The equine influenza segment accounted for 21.36% share in 2026.
  • By Distribution Channel: Veterinary hospitals and clinics held the largest share due to the growing number of specialized equine clinics globally.

Regional Insights

In 2026, North America generated USD 0.88 billion, driven by a large equine population of approximately 7.2 million horses in the U.S. Europe maintained a significant share due to disease outbreaks such as equine influenza. Asia Pacific is expected to grow at the fastest CAGR, with strong growth in China, Japan, and India, supported by increasing awareness and government initiatives.

Competitive Landscape

The market is fragmented, with key players including Zoetis Services LLC, Boehringer Ingelheim, Merck & Co., Dechra, Elanco, and Virbac. Companies are focusing on new product launches, geographic expansion, and strategic partnerships to strengthen their market presence.

Conclusion

In conclusion, the global equine health market is projected to grow from USD 2.21 billion in 2025 to USD 4.08 billion by 2034, driven by rising disease prevalence, increasing awareness of equine welfare, and continuous innovation in drugs and vaccines. While challenges such as veterinarian shortages and vaccine efficacy concerns persist, expanding preventive healthcare initiatives, advanced treatment options, and strategic efforts by key players are expected to support sustained market growth throughout the forecast period.

Segmentation By Product

  • Drug Class
    • Anti-Infective
    • Anti-Inflammatory
    • Parasiticides
    • Others
  • Vaccines
    • Inactivated
    • Live Attenuated
    • Recombinant
    • Others
  • Supplemental Feed Additives

By Disease Type

  • West Nile Virus
  • Equine Rabies
  • Equine Influenza
  • Equine Herpes Virus
  • Potomac Horse Fever
  • Tetanus
  • Others

By Distribution Channel

  • Veterinary Hospitals and Clinics
  • Retail Pharmacies and Drug Stores
  • Others

By Region

  • North America (By Product, Disease Type, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Product, Disease Type, Distribution Channel, and Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, Disease Type, Distribution Channel, and Country/Sub-Region)
    • China
    • India
    • Japan
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, Disease Type, Distribution Channel, and Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa (By Product, Disease Type, Distribution Channel, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Statistics: Equine Population, By Key Countries, 2025
  • 4.2. Regulatory Scenario, Equine Health, By Key Countries, 2025
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
  • 4.4. Technology Advances in Equine Health
  • 4.5. Impact of Covid-19 on the Market

5. Global Equine Health Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Drug Type
      • 5.1.1.1. Anti-Infectives
      • 5.1.1.2. Anti-Inflammatory
      • 5.1.1.3. Parasiticides
      • 5.1.1.4. Others
    • 5.1.2. Vaccine Type
      • 5.1.2.1. Inactivated
      • 5.1.2.2. Live Attenuated
      • 5.1.2.3. Recombinant
      • 5.1.2.4. Others
    • 5.1.3. Supplemental Feed Additives
  • 5.2. Market Analysis, Insights and Forecast - By Disease Type
    • 5.2.1. West Nile Virus
    • 5.2.2. Equine Rabies
    • 5.2.3. Equine Influenza
    • 5.2.4. Equine Herpes Virus
    • 5.2.5. Potomac Horse Fever
    • 5.2.6. Tetanus
    • 5.2.7. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Veterinary Hospitals and Clinics
    • 5.3.2. Retail Pharmacies and Drug Stores
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Equine Health Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Drug Type
      • 6.1.1.1. Anti-Infectives
      • 6.1.1.2. Anti-Inflammatory
      • 6.1.1.3. Parasiticides
      • 6.1.1.4. Others
    • 6.1.2. Vaccine Type
      • 6.1.2.1. Inactivated
      • 6.1.2.2. Live Attenuated
      • 6.1.2.3. Recombinant
      • 6.1.2.4. Others
    • 6.1.3. Supplemental Feed Additives
  • 6.2. Market Analysis, Insights and Forecast - By Disease Type
    • 6.2.1. West Nile Virus
    • 6.2.2. Equine Rabies
    • 6.2.3. Equine Influenza
    • 6.2.4. Equine Herpes Virus
    • 6.2.5. Potomac Horse Fever
    • 6.2.6. Tetanus
    • 6.2.7. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Veterinary Hospitals and Clinics
    • 6.3.2. Retail Pharmacies and Drug Stores
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Equine Health Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Drug Type
      • 7.1.1.1. Anti-Infectives
      • 7.1.1.2. Anti-Inflammatory
      • 7.1.1.3. Parasiticides
      • 7.1.1.4. Others
    • 7.1.2. Vaccine Type
      • 7.1.2.1. Inactivated
      • 7.1.2.2. Live Attenuated
      • 7.1.2.3. Recombinant
      • 7.1.2.4. Others
    • 7.1.3. Supplemental Feed Additives
  • 7.2. Market Analysis, Insights and Forecast - By Disease Type
    • 7.2.1. West Nile Virus
    • 7.2.2. Equine Rabies
    • 7.2.3. Equine Influenza
    • 7.2.4. Equine Herpes Virus
    • 7.2.5. Potomac Horse Fever
    • 7.2.6. Tetanus
    • 7.2.7. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Veterinary Hospitals and Clinics
    • 7.3.2. Retail Pharmacies and Drug Stores
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Equine Health Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Drug Type
      • 8.1.1.1. Anti-Infectives
      • 8.1.1.2. Anti-Inflammatory
      • 8.1.1.3. Parasiticides
      • 8.1.1.4. Others
    • 8.1.2. Vaccine Type
      • 8.1.2.1. Inactivated
      • 8.1.2.2. Live Attenuated
      • 8.1.2.3. Recombinant
      • 8.1.2.4. Others
    • 8.1.3. Supplemental Feed Additives
  • 8.2. Market Analysis, Insights and Forecast - By Disease Type
    • 8.2.1. West Nile Virus
    • 8.2.2. Equine Rabies
    • 8.2.3. Equine Influenza
    • 8.2.4. Equine Herpes Virus
    • 8.2.5. Potomac Horse Fever
    • 8.2.6. Tetanus
    • 8.2.7. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Veterinary Hospitals and Clinics
    • 8.3.2. Retail Pharmacies and Drug Stores
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Equine Health Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Drug Type
      • 9.1.1.1. Anti-Infectives
      • 9.1.1.2. Anti-Inflammatory
      • 9.1.1.3. Parasiticides
      • 9.1.1.4. Others
    • 9.1.2. Vaccine Type
      • 9.1.2.1. Inactivated
      • 9.1.2.2. Live Attenuated
      • 9.1.2.3. Recombinant
      • 9.1.2.4. Others
    • 9.1.3. Supplemental Feed Additives
  • 9.2. Market Analysis, Insights and Forecast - By Disease Type
    • 9.2.1. West Nile Virus
    • 9.2.2. Equine Rabies
    • 9.2.3. Equine Influenza
    • 9.2.4. Equine Herpes Virus
    • 9.2.5. Potomac Horse Fever
    • 9.2.6. Tetanus
    • 9.2.7. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Veterinary Hospitals and Clinics
    • 9.3.2. Retail Pharmacies and Drug Stores
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Equine Health Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Drug Type
      • 10.1.1.1. Anti-Infectives
      • 10.1.1.2. Anti-Inflammatory
      • 10.1.1.3. Parasiticides
      • 10.1.1.4. Others
    • 10.1.2. Vaccine Type
      • 10.1.2.1. Inactivated
      • 10.1.2.2. Live Attenuated
      • 10.1.2.3. Recombinant
      • 10.1.2.4. Others
    • 10.1.3. Supplemental Feed Additives
  • 10.2. Market Analysis, Insights and Forecast - By Disease Type
    • 10.2.1. West Nile Virus
    • 10.2.2. Equine Rabies
    • 10.2.3. Equine Influenza
    • 10.2.4. Equine Herpes Virus
    • 10.2.5. Potomac Horse Fever
    • 10.2.6. Tetanus
    • 10.2.7. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Veterinary Hospitals and Clinics
    • 10.3.2. Retail Pharmacies and Drug Stores
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Zoetis Services LLC
      • 11.2.1.1. Overview
      • 11.2.1.2. Product
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. financials (Based on Availability)
    • 11.2.2. Ceva
      • 11.2.2.1. Overview
      • 11.2.2.2. Product
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. financials (Based on Availability)
    • 11.2.3. Elanco
      • 11.2.3.1. Overview
      • 11.2.3.2. Product
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. financials (Based on Availability)
    • 11.2.4. Boehringer Ingelheim International GmbH
      • 11.2.4.1. Overview
      • 11.2.4.2. Product
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. financials (Based on Availability)
    • 11.2.5. Vetoquinol
      • 11.2.5.1. Overview
      • 11.2.5.2. Product
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. financials (Based on Availability)
    • 11.2.6. Neogen Corporation
      • 11.2.6.1. Overview
      • 11.2.6.2. Product
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. financials (Based on Availability)
    • 11.2.7. Virbac
      • 11.2.7.1. Overview
      • 11.2.7.2. Product
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. financials (Based on Availability)
    • 11.2.8. Merck & Co., Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Product
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. financials (Based on Availability)
    • 11.2.9. Norbrook
      • 11.2.9.1. Overview
      • 11.2.9.2. Product
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. financials (Based on Availability)
    • 11.2.10. Purina Animal Nutrition LLC.
      • 11.2.10.1. Overview
      • 11.2.10.2. Product
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. financials (Based on Availability)
    • 11.2.11. Kyoritsuseiyaku Corporation
      • 11.2.11.1. Overview
      • 11.2.11.2. Product
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. financials (Based on Availability)
    • 11.2.12. Equine Products UK Ltd.
      • 11.2.12.1. Overview
      • 11.2.12.2. Product
      • 11.2.12.3. SWOT Analysis
      • 11.2.12.4. Recent Developments
      • 11.2.12.5. Strategies
      • 11.2.12.6. financials (Based on Availability)

List of Tables

  • Table 01: Global Equine Health Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 02: Global Equine Health Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 03: Global Equine Health Market Revenue (USD billion) Forecast, By Vaccine Type, 2021-2034
  • Table 04: Global Equine Health Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 05: Global Equine Health Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 06: Global Equine Health Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 07: North America Equine Health Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 08: North America Equine Health Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 09: North America Equine Health Market Revenue (USD billion) Forecast, By Vaccine Type, 2021-2034
  • Table 10: North America Equine Health Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 11: North America Equine Health Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 12: North America Equine Health Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: Europe Equine Health Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 14: Europe Equine Health Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 15: Europe Equine Health Market Revenue (USD billion) Forecast, By Vaccine Type, 2021-2034
  • Table 16: Europe Equine Health Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 17: Europe Equine Health Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 18: Europe Equine Health Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
  • Table 19: Asia Pacific Equine Health Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 20: Asia Pacific Equine Health Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 21: Asia Pacific Equine Health Market Revenue (USD billion) Forecast, By Vaccine Type, 2021-2034
  • Table 22: Asia Pacific Equine Health Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 23: Asia Pacific Equine Health Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 24: Asia Pacific Equine Health Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
  • Table 25: Latin America Equine Health Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 26: Latin America Equine Health Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 27: Latin America Equine Health Market Revenue (USD billion) Forecast, By Vaccine Type, 2021-2034
  • Table 28: Latin America Equine Health Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 29: Latin America Equine Health Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 30: Latin America Equine Health Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
  • Table 31: Middle East & Africa Equine Health Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 32: Middle East & Africa Equine Health Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 33: Middle East & Africa Equine Health Market Revenue (USD billion) Forecast, By Vaccine Type, 2021-2034
  • Table 34: Sweden Equine Health Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 35: Middle East & Africa Equine Health Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 36: Middle East & Africa Equine Health Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034

List of Figures

  • Figure 01: Global Equine Health Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 02: Global Equine Health Market Value Share (%), By Product, 2025 & 2034
  • Figure 03: Global Equine Health Market Value Share (%), By Disease Type, 2025 & 2034
  • Figure 04: Global Equine Health Market Value Share (%), By Distribution Channel, 2025 & 2034
  • Figure 05: Global Equine Health Market Value Share (%), By Region, 2025 & 2034
  • Figure 06: North America Equine Health Market Value (USD billion), By Product, 2025 & 2034
  • Figure 07: North America Equine Health Market Value Share (%), By Product, 2025
  • Figure 08: North America Equine Health Market Value (USD billion), By Disease Type, 2025 & 2034
  • Figure 09: North America Equine Health Market Value Share (%), By Disease Type, 2025
  • Figure 10: North America Equine Health Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 11: North America Equine Health Market Value Share (%), By Distribution Channel, 2025
  • Figure 12: North America Equine Health Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Equine Health Market Value Share (%), By Country, 2025
  • Figure 14: Europe Equine Health Market Value (USD billion), By Product, 2025 & 2034
  • Figure 15: Europe Equine Health Market Value Share (%), By Product, 2025
  • Figure 16: Europe Equine Health Market Value (USD billion), By Disease Type, 2025 & 2034
  • Figure 17: Europe Equine Health Market Value Share (%), By Disease Type, 2025
  • Figure 18: Europe Equine Health Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 19: Europe Equine Health Market Value Share (%), By Distribution Channel, 2025
  • Figure 20: Europe Equine Health Market Value (USD billion), By Country/ Sub-Region, 2025 & 2034
  • Figure 21: Europe Equine Health Market Value Share (%), By Country/ Sub-Region, 2025
  • Figure 22: Asia Pacific Equine Health Market Value (USD billion), By Product, 2025 & 2034
  • Figure 23: Asia Pacific Equine Health Market Value Share (%), By Product, 2025
  • Figure 24: Asia Pacific Equine Health Market Value (USD billion), By Disease Type, 2025 & 2034
  • Figure 25: Asia Pacific Equine Health Market Value Share (%), By Disease Type, 2025
  • Figure 26: Asia Pacific Equine Health Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Equine Health Market Value Share (%), By Distribution Channel, 2025
  • Figure 28: Asia Pacific Equine Health Market Value (USD billion), By Country/ Sub-Region, 2025 & 2034
  • Figure 29: Asia Pacific Equine Health Market Value Share (%), By Country/ Sub-Region, 2025
  • Figure 30: Latin America Equine Health Market Value (USD billion), By Product, 2025 & 2034
  • Figure 31: Latin America Equine Health Market Value Share (%), By Product, 2025
  • Figure 32: Latin America Equine Health Market Value (USD billion), By Disease Type, 2025 & 2034
  • Figure 33: Latin America Equine Health Market Value Share (%), By Disease Type, 2025
  • Figure 34: Latin America Equine Health Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Equine Health Market Value Share (%), By Distribution Channel, 2025
  • Figure 36: Latin America Equine Health Market Value (USD billion), By Country/ Sub-Region, 2025 & 2034
  • Figure 37: Latin America Equine Health Market Value Share (%), By Country/ Sub-Region, 2025
  • Figure 38: Middle East & Africa Equine Health Market Value (USD billion), By Product, 2025 & 2034
  • Figure 39: Middle East & Africa Equine Health Market Value Share (%), By Product, 2025
  • Figure 40: Middle East & Africa Equine Health Market Value (USD billion), By Disease Type, 2025 & 2034
  • Figure 41: Middle East & Africa Equine Health Market Value Share (%), By Disease Type, 2025
  • Figure 42: Middle East & Africa Equine Health Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Equine Health Market Value Share (%), By Distribution Channel, 2025
  • Figure 44: Middle East & Africa Equine Health Market Value (USD billion), By Country/ Sub-Region, 2025 & 2034
  • Figure 45: Middle East & Africa Equine Health Market Value Share (%), By Country/ Sub-Region, 2025
  • Figure 46: The figure besides highlights the market share (%) of companies operating in the global equine health market, 2025.